See more : NYKREDIT INVEST SUSTAINABLE CRE (NYIBKO.CO) Income Statement Analysis – Financial Results
Complete financial analysis of PaxMedica, Inc. Common Stock (PXMD) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of PaxMedica, Inc. Common Stock, a leading company in the Biotechnology industry within the Healthcare sector.
- Vtech Holdings Limited (VTKLY) Income Statement Analysis – Financial Results
- PT Indo Pureco Pratama Tbk (IPPE.JK) Income Statement Analysis – Financial Results
- Talen Energy Corporation (TLN) Income Statement Analysis – Financial Results
- Vishwaraj Sugar Industries Limited (VISHWARAJ.BO) Income Statement Analysis – Financial Results
- DP Poland Plc (DPP.L) Income Statement Analysis – Financial Results
PaxMedica, Inc. Common Stock (PXMD)
About PaxMedica, Inc. Common Stock
PaxMedica, Inc., a clinical stage biopharmaceutical company, focuses on the development of anti-purinergic drug therapies (APT) for the treatment of disorders with intractable neurologic symptoms. The company's lead product candidate is PAX-101, an intravenous formulation of suramin for various indications, including autism spectrum disorder, myalgic encephalomyelitis/chronic fatigue syndrome, long COVID-19 syndrome, and human african trypanosomiasis. It is also involved in developing PAX-102, an intranasal formulation of suramin for neurologic indications. The company was formerly known as Purinix Pharmaceuticals LLC and changed its name to PaxMedica, Inc. in April 2020. PaxMedica, Inc. was incorporated in 2018 and is based in Tarrytown, New York. PaxMedica, Inc. operates as a subsidiary of Tardimed Sciences LLC.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 3.91M | 1.79M | 2.22M | 936.78K | 484.11K |
| General & Administrative | 12.23B | 8.82M | 4.97M | 4.63M | 114.50K |
| Selling & Marketing | -12.22B | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 12.23M | 8.82M | 4.97M | 4.63M | 114.50K |
| Other Expenses | 0.00 | -5.51M | 173.35K | -53.54K | 0.00 |
| Operating Expenses | 16.15M | 10.60M | 7.20M | 5.57M | 598.61K |
| Cost & Expenses | 16.15M | 10.60M | 7.20M | 5.57M | 598.61K |
| Interest Income | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 9.17K | 5.24K | 2.81M | 609.46K | 0.00 |
| Depreciation & Amortization | 167.90K | -5.90M | 173.35K | -53.54K | 171.86K |
| EBITDA | -16.15M | -10.60M | -7.20M | -5.62M | -598.61K |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -16.15M | -10.60M | -7.20M | -5.57M | -598.61K |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | -2.14M | -4.20M | -3.03M | -2.26M | 0.00 |
| Income Before Tax | -18.29M | -14.80M | -10.23M | -7.83M | -598.61K |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | -167.90K | 4.19M | 2.81M | 663.00K | -171.86K |
| Net Income | -18.29M | -14.80M | -13.03M | -8.49M | -598.61K |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -11.00 | -28.79 | -18.81 | -12.25 | -0.06 |
| EPS Diluted | -11.00 | -28.79 | -18.81 | -12.25 | -0.06 |
| Weighted Avg Shares Out | 1.66M | 514.22K | 692.91K | 692.91K | 10.02M |
| Weighted Avg Shares Out (Dil) | 1.66M | 514.22K | 692.91K | 692.91K | 10.02M |
PaxMedica Secures Immediate Exercise of Warrants
PaxMedica Reports First Patient Treated with PAX-101 for Fatal African Sleeping Sickness Infection
PaxMedica Files Nasdaq Delisting Appeal Notice and Prepares for Upcoming FDA Meeting on PAX-101
PaxMedica Responds to Emergency Request for IV Suramin and Commits to Provide Immediate Access to PAX-101
PaxMedica Receives Emergency Request for IV Suramin from African Health Ministry for Use in Treating Fatal Sleeping Sickness
Choosing Unknown Penny Stocks, 3 Top Tips
Why is PaxMedica (PXMD) stock surging today?
Why is PaxMedica (PXMD) stock surging today?
Why Is PaxMedica (PXMD) Stock Up 93% Today?
PaxMedica Achieves Key Milestone in the Development of PAX-101 And Provides Update on Potential NDA Submission
Source: https://incomestatements.info
Category: Stock Reports